Xeomin is free from complexing proteins

被引：43
作者：
Frevert, Juergen [1 ]
机构：
[1] Merz Pharmaceut GmbH, D-14473 Potsdam, Germany
来源：
TOXICON | 2009年 / 54卷 / 05期
关键词：
Botulinum toxin; Complexing proteins efficacy; A FREE; BOTULINUM; DYSTONIA;
D O I：
10.1016/j.toxicon.2009.03.010
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
In contrast to the other botulinum toxin products Xeomin only contains the 150 kD neurotoxin without complexing proteins which have no therapeutic function and don't influence the diffusion of the neurotoxin. In large clinical Phase III studies (blepharospasm and cervical dystonia) Xeomin showed the same efficacy and profile of adverse events as Botox. Whereas competing product must be stored refrigerated, Xeomin is stable for 3 years at room temperature. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码：697 / 701
页数：5
相关论文
共 9 条
[1]   A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia [J].
Benecke, R ;
Jost, WH ;
Kanovsky, P ;
Ruzicka, E ;
Comes, G ;
Grafe, S .
NEUROLOGY, 2005, 64 (11) :1949-1951
[2]   An histological assessment of diffusion of different botulinum neurotoxin type A formulations injected in the mice leg [J].
Carli, Luca ;
Montecucco, Cesare ;
Rossetto, Ornella .
TOXICON, 2008, 51 :9-9
[3]   Equivalent potency of Xeomin® and BOTOX® [J].
Dressler, Dirk ;
Mander, Gerd J. ;
Fink, Klaus .
TOXICON, 2008, 51 :10-10
[4]   Dissociation of the 900 kDa neurotoxin complex from C. botulinum under physiological conditions [J].
Eisele, Karl-Heinz ;
Taylor, Harold V. .
TOXICON, 2008, 51 :10-10
[5]   Xeomin® is stable without refrigeration:: Complexing proteins are not required for stability of botulinum neurotoxin type A preparations [J].
Grein, Swen ;
Mander, Gerd J. ;
Taylor, Harold V. .
TOXICON, 2008, 51 :13-13
[6]   Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia [J].
Jost, Wolfgang H. ;
Bluemel, Joerg ;
Grafe, Susanne .
DRUGS, 2007, 67 (05) :669-683
[7]   Production of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B16S toxin-haemagglutinin [J].
Lee, JC ;
Yokota, K ;
Arimitsu, H ;
Hwang, HJ ;
Sakaguchi, Y ;
Cui, JH ;
Takeshi, K ;
Watanabe, T ;
Ohyama, T ;
Oguma, K .
MICROBIOLOGY-SGM, 2005, 151 :3739-3747
[8]   Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm [J].
Roggenkämper, P ;
Jost, WH ;
Bihari, K ;
Comes, G ;
Grafe, S .
JOURNAL OF NEURAL TRANSMISSION, 2006, 113 (03) :303-312
[9]   Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins [J].
Wohlfarth, Kai ;
Mueller, Christian ;
Sassin, Irena ;
Comes, Georg ;
Grafe, Susanne .
CLINICAL NEUROPHARMACOLOGY, 2007, 30 (02) :86-94
1